1.
晚期肺癌患者临床特征、IGF-1R和IGF-2R的基因型与铂类化疗疗效的关系
The relationship among clinical features, IGF-1R and IGF-2R genotypes and efficacy of platinum- based chemotherapy
| Characteristics | n | CR+PR+SD (%)d | PD (%)d | OR (95%CI)e | Pe |
| a SCC: squamous cell carcinoma; AC: adenocarcinoma; Others: include adenosquamocarcinoma, bronchioloalveolar carcinoma, large-cell carcinomas, unclassified non-small cell lung eancer. b IP: cisplatin/carboplatin+CPT-11; GP: cisplatin/carboplatin+gemcitabine; NP: cisplatin/carboplatin+vinorelbine; TP: cisplatin/carboplatin+paclitaxel/docetaxel; DDP+PEM: cisplatin+pemet rexed disodium.c Genotypes with A allele (either the heterozygous GA or the homozygous AA genotypes); d CR:complete response; PR: partial response; SD:stable disease; PD: progression disease. e Adjusted for age, gender, smoking status, histology, clinical stage, chemotherapy regimen and IGF-1R and IGF-2R. | |||||
| Gender | |||||
| Female | 47 | 39 (83.0) | 8 (17.0) | ||
| Male | 85 | 61 (71.8) | 24 (28.2) | 0.25 (0.07-0.83) | 0.023 |
| Age (year) | |||||
| ＜60 | 65 | 47 (72.3) | 18 (27.7) | ||
| ≥60 | 67 | 53 (79.1) | 14 (20.9) | 2.15 (0.80-5.80) | 0.129 |
| Smoking status | |||||
| No smoking | 65 | 47 (72.3) | 18 (27.7) | ||
| Smoking | 67 | 53 (79.1) | 14 (20.9) | 3.23 (0.99-10.58) | 0.053 |
| Histologya | |||||
| SCC | 33 | 29 (79.9) | 4 (12.1) | 1.00 | - |
| AC | 70 | 51 (72.9) | 19 (27.1) | 0.42 (0.11-1.55) | 0.190 |
| Others | 29 | 20 (69.0) | 9 (31.0) | 0.39 (0.08-1.91) | 0.340 |
| pTNM stage | |||||
| Ⅲ | 53 | 46 (86.8) | 7 (13.2) | ||
| Ⅳ | 79 | 54 (68.4) | 25 (31.6) | 0.40 (0.14-1.10) | 0.076 |
| Chemotherapy regimenb | |||||
| IP | 14 | 9 (64.3) | 5 (35.7) | 1.00 | - |
| GP | 46 | 34 (73.9) | 12 (26.1) | 1.11 (0.20-6.18) | 0.905 |
| NP | 28 | 23 (82.1) | 5 (17.9) | 1.55 (0.24-9.91) | 0.645 |
| TP | 31 | 24 (77.4) | 7 (22.6) | 1.47 (0.24-9.05) | 0.676 |
| DDP+PEM | 13 | 10 (76.9) | 3 (23.1) | 1.37 (0.19-9.68) | 0.753 |
| IGF-1R | |||||
| GG | 49 | 37 (75.5) | 12 (24.5) | 1.00 | - |
| GA | 69 | 52 (75.4) | 17 (24.6) | 0.85 (0.34-2.16) | 0.739 |
| AA | 14 | 11 (78.6) | 3 (21.4) | 0.88 (0.18-4.34) | 0.879 |
| GA+AAc | 83 | 63 (75.9) | 20 (24.1) | 0.86 (0.35-2.10) | 0.737 |
| IGF-2R | |||||
| GG | 81 | 61 (75.3) | 20 (24.7) | 1.00 | - |
| GA | 47 | 36 (76.6) | 11 (23.4) | 1.23 (0.47-3.23) | 0.672 |
| AA | 4 | 3 (75.0) | 1 (25.0) | 1.27 (0.10-16.46) | 0.875 |
| GA+AAc | 51 | 39 (76.5) | 12 (23.5) | 1.24 (0.49-3.13) | 0.656 |